GlassScriptPhysician profile
Romeo A Mandanas
NPI 1114974466
$160,079.45
in general payments reported to CMS, 2019-2025
41 companies · $4,063 in 2025
The $4,063 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $23K · 2021: $21K · 2022: $27K · 2023: $17K · 2024: $4,741 · 2025: $4,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $7,772 · Travel and Lodging: $4,125 · Food and Beverage: $1,904 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,331.50 |
| Consulting Fee | $7,771.75 |
| Travel and Lodging | $4,125.11 |
| Food and Beverage | $1,904.16 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $257.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $38,638.53 | 2019-2025 | Reblozyl |
| Janssen Biotech, INC. | $38,147.19 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Novartis Pharmaceuticals Corporation | $28,056.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $15,655.22 | 2019-2025 | Imfinzi, Enhertu |
| Mirati Therapeutics, INC. | $7,294.94 | 2023 | Krazati |
| Incyte Corporation | $6,429.67 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $5,848.61 | 2019-2025 | Reblozyl, Opdivo |
| Seagen INC. | $4,630.89 | 2019-2022 | |
| Genzyme Corporation | $2,667.40 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $2,600.77 | 2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $2,572.41 | 2019-2025 | |
| Array Biopharma INC | $2,422.45 | 2019-2021 | |
| Tg Therapeutics, INC. | $2,025.00 | 2021 | |
| Pfizer INC. | $716.56 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $708.75 | 2024-2025 | Talvey |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $550.00 | 2021 | |
| Galvanize Therapeutics, INC | $176.58 | 2025 | Aliya System |
| Abbvie INC. | $169.23 | 2019-2025 | |
| Blueprint Medicines Corporation | $154.95 | 2020-2024 | Ayvakit |
| Astellas Pharma US INC | $123.59 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $71.79 | 2023-2024 | Orgovyx |
| Merck Sharp & Dohme LLC | $59.32 | 2019-2025 | Keytruda, Keytruda Qlex |
| Lilly USA, LLC | $41.91 | 2019-2020 | |
| Caris Mpi, INC. | $40.90 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $40.86 | 2019-2021 | |
| Amgen INC. | $34.18 | 2019 | |
| Genmab U.S., INC. | $24.58 | 2024 | Epkinly |
| Sobi, INC | $24.06 | 2025 | |
| Stemline Therapeutics INC. | $20.81 | 2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $20.21 | 2019 | |
| Genentech USA, INC. | $19.81 | 2025 | Polivy |
| Regeneron Healthcare Solutions, INC. | $18.91 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $18.36 | 2019 | |
| Clovis Oncology, INC. | $15.28 | 2019 | |
| Rigel Pharmaceuticals, INC. | $14.34 | 2019 | |
| Daiichi Sankyo INC. | $13.91 | 2019 | |
| Exelixis INC. | $11.00 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romeo Mandanas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.